PGLa |
Catalog No.GC32319 |
Le PGLa, un peptide À 21 résidus, est un peptide antimicrobien.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 102068-15-5
Sample solution is provided at 25 µL, 10mM.
PGLa is an antimicrobial peptide. PGLa is known to be bacteriostatic against both Gram-positive and Gram-negative bacteria.
PGLa is known to be bacteriostatic against both Gram-positive and Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Streptococcus pyogenes, and Staphylococcus aureus), without much selectivity between the two types of bacterial cells. PGLa is synthesized as a native (the wild type) peptide and as a mutant with a norleucine instead of methionine at position 2Met (designated PGLa(Nle)).
[1]. Radchenko DS, et al. Does a methionine-to-norleucine substitution in PGLa influence peptide-membrane interactions? Biochim Biophys Acta. 2016 Sep;1858(9):2019-27.
Average Rating: 5
(Based on Reviews and 40 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *